VRTX
VERTEX PHARMACEUTICALS INC / MA
$444.93
-0.02%
$112.9B
No data for this timeframe.
Vol
Market Cap$112.9B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (83%)
Inst. Holders50 funds
Inst. Value$76.3B
Inst. Activity30 buys / 20 sells
Insider Activity0B / 23S
Insider Net $-$16.7M
SEC Reports10
Congressional1 trades
Recent Activity
Aug 3, 2026
earnings_calendar
VRTX Q2 2026 Earnings After Market Close — 2026-08-03
EPS est: $4.85 | Rev est: $3.3B
Jun 5, 2026
Insider
Bozic Carmen sold 1,745 shares
EVP and CMO @ $450.00 ($785.3K)
Jun 3, 2026
SEC
Two senior executives at Vertex Pharmaceuticals (EVP/CMO and EVP/Chief Legal Officer) sold a combined $1.25M in open-mar
CLUSTER — Impact 2/10
Jun 1, 2026
Insider
Liu Joy sold 828 shares
EVP and Chief Legal Officer @ $439.91 ($364.2K)
May 31, 2026
SEC
20 firms acted on VRTX: Maxim Group, Jefferies, Oppenheimer, Barclays, RBC Capital, Bernstein, Wolfe Research, Morgan Stanley, Leerink Partners, Raymond James, Wells Fargo, Leerink Partners, Canaccord Genuity, Wells Fargo, Oppenheimer, Jefferies, Citigroup, Scotiabank, Barclays, Redburn Atlantic
ANALYST-UPGRADE — Impact 1/10
May 29, 2026
Insider
Bozic Carmen sold 1,974 shares
EVP and CMO @ $450.00 ($888.3K)
May 1, 2026
SEC
Maxim Group upgrades VRTX to Buy, PT $575 (+35%) — cluster of 20 firms active on the name
ANALYST-UPGRADE — Impact 1/10
Inst.
VICTORY CAPITAL MANAGEMENT INC — TRIM
1,888,521 shares ($843.3M)
Price Targets
$548.69
+23.3% upside
Strong Buy
Current $444.93
Low $330.00
Median $555.00
High $641.00
29 analysts
$330.00
$641.00
Analyst Ratings
13Strong Buy
20Buy
6Hold
0Sell
1Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 6, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| May 5, 2026 | Canaccord Genuity | MAINTAIN | Hold → Hold |
| May 5, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
| May 5, 2026 | Bernstein | MAINTAIN | Outperform → Outperform |
| May 5, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $4.73 | $4.26 — $5.16 | 5% YoY | 24 |
| Next Q | $4.95 | $4.69 — $5.60 | 3% YoY | 23 |
| Current FY | $19.15 | $18.42 — $20.73 | 4% YoY | 28 |
| Next FY | $21.47 ▼ -0.5% | $18.77 — $24.64 | 12% YoY | 27 |
Latest Reports
BULLISH
ANALYST-UPGRADE
1/10
20 firms acted on VRTX: Maxim Group, Jefferies, Oppenheimer, Barclays, RBC Capital, Bernstein, Wolfe Research, Morgan Stanley, Leerink Partners, Raymond James, Wells Fargo, Leerink Partners, Canaccord Genuity, Wells Fargo, Oppenheimer, Jefferies, Citigroup, Scotiabank, Barclays, Redburn Atlantic
May 31, 2026
MIXED
ANALYST-UPGRADE
1/10
Maxim Group upgrades VRTX to Buy, PT $575 (+35%) — cluster of 20 firms active on the name
May 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Capital World Investors | $11.3B | — |
| BlackRock, Inc. | $10.7B | — |
| Capital Research Global Investors | $9.4B | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $7.4B | — |
| STATE STREET CORP | $5.2B | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Bozic Carmen | SELL | $785.3K |
| Jun 1, 2026 | Liu Joy | SELL | $364.2K |
| May 29, 2026 | Bozic Carmen | SELL | $888.3K |
| May 15, 2026 | Bozic Carmen | SELL | $614.0K |
| May 15, 2026 | Bunnage Mark | SELL | $15.0K |
Congressional Trades
1 members: 1 buys, 0 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Ro Khanna | D | BUY | $1,001 - $15,000 |
50 institutional holders with $76.3B total value (170,865,947 shares) as of 2026-Q1. Top holders: Capital, BlackRock,, Capital. Net buying activity: 30 institutions added/increased vs 20 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Capital World Investors | 25,368,124 | $11.3B | 14.8% | — |
| 2 | BlackRock, Inc. | 23,969,517 | $10.7B | 14.0% | — |
| 3 | Capital Research Global Investors | 21,125,964 | $9.4B | 12.4% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 16,512,810 | $7.4B | 9.7% | — |
| 5 | STATE STREET CORP | 11,730,139 | $5.2B | 6.9% | — |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5,145,609 | $2.3B | 3.0% | — |
| 7 | Capital International Investors | 5,126,077 | $2.3B | 3.0% | — |
| 8 | LOOMIS SAYLES & CO L P | 4,003,821 | $1.8B | 2.3% | — |
| 9 | ALLIANCEBERNSTEIN L.P. | 3,910,786 | $1.8B | 2.3% | — |
| 10 | WELLINGTON MANAGEMENT GROUP LLP | 3,212,589 | $1.4B | 1.9% | — |
| 11 | MORGAN STANLEY | 3,188,881 | $1.4B | 1.9% | — |
| 12 | BANK OF AMERICA CORP /DE/ | 2,878,183 | $1.3B | 1.7% | — |
| 13 | JENNISON ASSOCIATES LLC | 2,740,059 | $1.2B | 1.6% | — |
| 14 | Clearbridge Investments, LLC | 2,700,975 | $1.2B | 1.6% | — |
| 15 | AMERIPRISE FINANCIAL INC | 2,633,481 | $1.2B | 1.5% | — |
| 16 | Invesco Ltd. | 2,561,057 | $1.1B | 1.5% | — |
| 17 | GOLDMAN SACHS GROUP INC | 2,417,875 | $1.1B | 1.4% | — |
| 18 | JANUS HENDERSON GROUP PLC | 2,131,527 | $951.8M | 1.2% | — |
| 19 | FMR LLC | 2,020,265 | $902.1M | 1.2% | — |
| 20 | Legal & General Group Plc | 1,955,764 | $873.3M | 1.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VICTORY CAPITAL MANAGEMENT INC | TRIM | 3,356,766 | 1,888,521 | -43.7% | $843.3M | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 669,807 | 848,047 | +26.6% | $378.7M | 2026-Q1 |
| Assenagon Asset Management S.A. | TRIM | 832,853 | 537,248 | -35.5% | $239.9M | 2026-Q1 |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | TRIM | 803,773 | 364,513 | -54.6% | $162.8M | 2026-Q1 |
| Pictet Asset Management Holding SA | TRIM | 752,425 | 337,569 | -55.1% | $150.1M | 2026-Q1 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | ADD | 211,934 | 327,498 | +54.5% | $149.4M | 2026-Q1 |
| MARSHALL WACE, LLP | ADD | 204,032 | 317,058 | +55.4% | $141.6M | 2026-Q1 |
| AMF Tjanstepension AB | DOUBLED | 145,949 | 312,917 | +114.4% | $139.7M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | ADD | 201,290 | 306,461 | +52.2% | $136.8M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | 345,383 | 251,711 | -27.1% | $112.4M | 2026-Q1 |
| AGF MANAGEMENT LTD | DOUBLED | 568 | 201,403 | +35358.3% | $89.9M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | ADD | 123,252 | 163,898 | +33.0% | $72.6M | 2026-Q1 |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | ADD | 89,062 | 149,962 | +68.4% | $67.0M | 2026-Q1 |
| SEI INVESTMENTS CO | TRIM | 364,023 | 133,226 | -63.4% | $59.5M | 2026-Q1 |
| CAPITAL FUND MANAGEMENT S.A. | NEW | — | 122,934 | — | $54.9M | 2026-Q1 |
| CREDIT AGRICOLE S A | DOUBLED | 46,894 | 122,365 | +160.9% | $54.6M | 2026-Q1 |
| MACKENZIE FINANCIAL CORP | ADD | 63,299 | 96,709 | +52.8% | $43.2M | 2026-Q1 |
| Erste Asset Management GmbH | ADD | 67,363 | 91,958 | +36.5% | $40.8M | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 22,158 | 88,499 | +299.4% | $39.5M | 2026-Q1 |
| Tredje AP-fonden | TRIM | 131,727 | 73,799 | -44.0% | $33.0M | 2026-Q1 |
| Holocene Advisors, LP | DOUBLED | 1,478 | 67,618 | +4475.0% | $30.2M | 2026-Q1 |
| HighTower Advisors, LLC | ADD | 47,559 | 65,684 | +38.1% | $29.3M | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | NEAR_EXIT | 293,301 | 64,937 | -77.9% | $29.0M | 2026-Q1 |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | ADD | 47,245 | 61,867 | +30.9% | $27.6M | 2026-Q1 |
| ASSETMARK, INC | TRIM | 90,483 | 59,954 | -33.7% | $26.8M | 2026-Q1 |
20 unique insiders with 50 transactions. Net insider value: -$16.7M ($0.00 bought, $16.7M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Bozic Carmen | EVP and CMO | SELL | 1,745 | $450.00 | $785.3K |
| Jun 1, 2026 | Liu Joy | EVP and Chief Legal Officer | SELL | 828 | $439.91 | $364.2K |
| May 29, 2026 | Bozic Carmen | EVP and CMO | SELL | 1,974 | $450.00 | $888.3K |
| May 15, 2026 | Bozic Carmen | EVP and CMO | SELL | 1,354 | $453.45 | $614.0K |
| May 15, 2026 | Bunnage Mark E. | EVP, Chief Scientific Officer | SELL | 33 | $453.45 | $15.0K |
| May 12, 2026 | Bozic Carmen | EVP and CMO | SELL | 6,988 | $450.00 | $3.1M |
| May 4, 2026 | Bhatia Sangeeta N. | Director | SELL | 318 | $423.73 | $134.7K |
| May 1, 2026 | MCKENZIE DIANA | Director | AWARD | 796 | — | — |
| May 1, 2026 | MCKENZIE DIANA | Director | AWARD | 943 | — | — |
| May 1, 2026 | MCKENZIE DIANA | Director | D | 796 | — | — |
| May 1, 2026 | SACHS BRUCE I | Director | AWARD | 2,866 | — | — |
| May 1, 2026 | Schneider Jennifer | Director | AWARD | 472 | — | — |
| May 1, 2026 | Schneider Jennifer | Director | D | 796 | — | — |
| May 1, 2026 | Schneider Jennifer | Director | AWARD | 1,433 | — | — |
| May 1, 2026 | Schneider Jennifer | Director | AWARD | 796 | — | — |
| May 1, 2026 | Thornberry Nancy | Director | AWARD | 472 | — | — |
| May 1, 2026 | Thornberry Nancy | Director | D | 398 | — | — |
| May 1, 2026 | Thornberry Nancy | Director | AWARD | 1,433 | — | — |
| May 1, 2026 | Thornberry Nancy | Director | AWARD | 398 | — | — |
| May 1, 2026 | Bhatia Sangeeta N. | Director | AWARD | 943 | — | — |
| May 1, 2026 | Upadhyay Suketu | Director | D | 796 | — | — |
| May 1, 2026 | Upadhyay Suketu | Director | AWARD | 2,866 | — | — |
| May 1, 2026 | Upadhyay Suketu | Director | AWARD | 796 | — | — |
| May 1, 2026 | CARNEY LLOYD | Director | AWARD | 2,866 | — | — |
| May 1, 2026 | Garber Alan M | Director | AWARD | 472 | — | — |
| May 1, 2026 | Garber Alan M | Director | AWARD | 1,433 | — | — |
| May 1, 2026 | Lagarde Michel | Director | AWARD | 2,866 | — | — |
| May 1, 2026 | Liu Joy | EVP and Chief Legal Officer | SELL | 1,104 | $425.02 | $469.2K |
| Apr 15, 2026 | SACHS BRUCE I | Director | AWARD | 107.345 | $442.50 | $47.5K |
| Apr 15, 2026 | Garber Alan M | Director | AWARD | 33.898 | $442.50 | $15.0K |
| Apr 15, 2026 | Upadhyay Suketu | Director | AWARD | 80.508 | $442.50 | $35.6K |
| Apr 1, 2026 | Liu Joy | EVP and Chief Legal Officer | SELL | 978 | $449.17 | $439.3K |
| Mar 27, 2026 | Bozic Carmen | EVP and CMO | SELL | 2,329 | $450.95 | $1.1M |
| Mar 13, 2026 | Bozic Carmen | EVP and CMO | SELL | 2,329 | $481.79 | $1.1M |
| Mar 11, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | SELL | 2,633 | $498.42 | $1.3M |
| Mar 4, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | SELL | 2,437 | $475.30 | $1.2M |
| Mar 2, 2026 | Liu Joy | EVP and Chief Legal Officer | SELL | 892 | $495.96 | $442.4K |
| Feb 27, 2026 | Bozic Carmen | EVP and CMO | SELL | 2,329 | $480.31 | $1.1M |
| Feb 27, 2026 | Kewalramani Reshma | CEO & President | SELL | 400 | $479.75 | $191.9K |
| Feb 25, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | SELL | 260 | $486.35 | $126.5K |
| Feb 25, 2026 | Bunnage Mark E. | EVP, Chief Scientific Officer | SELL | 620 | $486.35 | $301.5K |
| Feb 25, 2026 | Ambrose Kristen | SVP & Chief Accounting Officer | SELL | 223 | $486.35 | $108.5K |
| Feb 25, 2026 | Biller Jonathan | EVP and Chief Legal Officer | SELL | 945 | $486.35 | $459.6K |
| Feb 25, 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | SELL | 1,846 | $486.35 | $897.8K |
| Feb 25, 2026 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | SELL | 668 | $486.35 | $324.9K |
| Feb 25, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | SELL | 2,500 | $486.35 | $1.2M |
| Feb 24, 2026 | WAGNER CHARLES F JR | EVP, CO & FO | TAX W/H | 1,744 | $485.11 | $846.0K |
| Feb 24, 2026 | Bunnage Mark E. | EVP, Chief Scientific Officer | TAX W/H | 582 | $485.11 | $282.3K |
| Feb 24, 2026 | Biller Jonathan | EVP and Chief Legal Officer | TAX W/H | 1,144 | $485.11 | $555.0K |
| Feb 24, 2026 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | TAX W/H | 1,627 | $485.11 | $789.3K |
10 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 1 mixed, 7 neutral. Avg impact: 2.9/10.
MIXED
ANALYST-UPGRADE
1/10
Maxim Group upgrades VRTX to Buy, PT $575 (+35%) — cluster of 20 firms active on the name
May 1, 2026
BULLISH
ANALYST-UPGRADE
1/10
20 firms acted on VRTX: Maxim Group, Jefferies, Oppenheimer, Barclays, RBC Capital, Bernstein, Wolfe Research, Morgan Stanley, Leerink Partners, Raymond James, Wells Fargo, Leerink Partners, Canaccord Genuity, Wells Fargo, Oppenheimer, Jefferies, Citigroup, Scotiabank, Barclays, Redburn Atlantic
May 31, 2026
NEUTRAL
CLUSTER
2/10
Two senior executives at Vertex Pharmaceuticals (EVP/CMO and EVP/Chief Legal Officer) sold a combine
Jun 3, 2026
NEUTRAL
CLUSTER
2/10
Two EVP-level insiders at Vertex (CMO and Chief Scientific Officer) sold open-market shares on the s
May 19, 2026
NEUTRAL
CLUSTER
3/10
Two Vertex Pharmaceuticals EVPs — the Chief Medical Officer and Chief Commercial Officer — sold shar
Mar 17, 2026
NEUTRAL
CLUSTER
4/10
Two Vertex Pharmaceuticals EVPs — the Chief Commercial Officer and Chief Legal Officer — sold shares
Mar 6, 2026
BEARISH
CLUSTER
6/10
Three senior executives at Vertex Pharmaceuticals — including the CEO and two EVPs — sold shares in
Mar 4, 2026
NEUTRAL
CLUSTER
3/10
Seven executives at Vertex Pharmaceuticals sold shares in a coordinated cluster over a 3-day window,
Mar 3, 2026
NEUTRAL
CLUSTER
4/10
Seven Vertex Pharmaceuticals executives sold shares in the past week, including open-market sales to
Feb 26, 2026
NEUTRAL
CLUSTER
3/10
Two executives at Vertex Pharmaceuticals executed open-market share sales totaling $433K, while the
Feb 26, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (83% buy). Based on 40 analysts: 13 strong buy, 20 buy, 6 hold, 0 sell, 1 strong sell.
Analyst Price Targets
$548.69 mean target
+23.3% upside
Strong Buy (1.61)
$330.00 Low
$641.00 High
| Metric | Value |
|---|---|
| Current Price | $444.93 |
| Target Low | $330.00 |
| Target Mean | $548.69 |
| Target Median | $555.00 |
| Target High | $641.00 |
| # Analysts | 29 |
| Recommendation | Strong Buy (1.61) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$4.73 | $4.26 | $5.16 | 4.6% | -0.3% | 9↑ 9↓ | $3.2B | 8.4% | 24 |
| Next Q 2026-09-30 |
$4.95 | $4.69 | $5.60 | 3.1% | -0.1% | 7↑ 10↓ | $3.3B | 8.8% | 23 |
| Current FY 2026-12-31 |
$19.15 | $18.42 | $20.73 | 4.0% | -0.1% | 14↑ 10↓ | $13.0B | 8.6% | 28 |
| Next FY 2027-12-31 |
$21.47 | $18.77 | $24.64 | 12.1% | -0.5% | 8↑ 14↓ | $14.3B | 9.4% | 27 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $4.727 | |
| 7d ago | $4.727 | |
| 30d ago | $4.742 | -0.015 |
| 60d ago | $4.726 | +0.001 |
| 90d ago | $4.733 | -0.007 |
18 analyst firms have rated this stock: 6 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 6, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| May 5, 2026 | Canaccord Genuity | MAINTAIN | Hold | Hold |
| May 5, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| May 5, 2026 | Bernstein | MAINTAIN | Outperform | Outperform |
| May 5, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 30, 2026 | Canaccord Genuity | MAINTAIN | Hold | Hold |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Mar 18, 2026 | Maxim Group | UPGRADE | Hold | Buy |
| Mar 11, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Mar 10, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Mar 10, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Mar 10, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 10, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Mar 10, 2026 | Jefferies | INITIATE | — | Buy |
| Mar 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 17, 2026 | Canaccord Genuity | MAINTAIN | Hold | Hold |
| Feb 17, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Feb 17, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 13, 2026 | Scotiabank | MAINTAIN | Sector Perform | Sector Perform |
| Feb 13, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 13, 2026 | Stifel | MAINTAIN | Hold | Hold |
| Feb 13, 2026 | Oppenheimer | UPGRADE | Perform | Outperform |
| Feb 13, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 28, 2026 | Barclays | UPGRADE | Equal-Weight | Overweight |
| Jan 26, 2026 | UBS | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Jan 22, 2026 | RBC Capital | UPGRADE | Sector Perform | Outperform |
| Jan 12, 2026 | Bernstein | UPGRADE | Market Perform | Outperform |
| Jan 6, 2026 | Wolfe Research | UPGRADE | Peer Perform | Outperform |
| Dec 29, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 13 | 20 | 6 | 0 | 1 | 83% | |
| May 1, 2026 | 13 | 19 | 6 | 0 | 1 | 82% | |
| Apr 1, 2026 | 13 | 20 | 6 | 0 | 1 | 83% | |
| Mar 1, 2026 | 12 | 19 | 7 | 0 | 1 | 79% | |
| Feb 1, 2026 | 11 | 19 | 8 | 0 | 1 | 77% | |
| Jan 1, 2026 | 9 | 17 | 12 | 0 | 1 | 67% | |
| Dec 1, 2025 | 9 | 16 | 13 | 0 | 1 | 64% | |
| Nov 1, 2025 | 9 | 16 | 13 | 0 | 1 | 64% |
Strong BuyBuyHoldSellStrong Sell
1 members of Congress traded this stock: 1 buys, 0 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | Vertex Pharmaceuticals Inc | May 13, 2026 (31d) |
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Aug 3, 2026
earnings_calendar
VRTX Q2 2026 Earnings After Market Close — 2026-08-03
EPS est: $4.85 | Rev est: $3.3B
May 29, 2026
Clinical Trial
A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy
Phase Phase 2 — COMPLETED
May 25, 2026
dark_pool
Dark Pool: VRTX — 1.2M shares, 48,559 trades
Week starting 2026-05-25. Total ATS volume: 1,164,430 shares across 48,559 trades.
May 18, 2026
dark_pool
Dark Pool: VRTX — 2.4M shares, 63,833 trades
Week starting 2026-05-18. Total ATS volume: 2,422,905 shares across 63,833 trades.
May 12, 2026
short_volume
Short Volume: VRTX — 61.2% short (0.3M / 0.5M)
Short: 324,565 | Exempt: 317 | TRF Vol: 530,396 | Short Ratio: 61.2% | Off-exchange volume (dark pool + OTC)
May 11, 2026
dark_pool
Dark Pool: VRTX — 1.5M shares, 60,114 trades
Week starting 2026-05-11. Total ATS volume: 1,529,673 shares across 60,114 trades.
May 5, 2026
short_volume
Short Volume: VRTX — 63.3% short (0.5M / 0.8M)
Short: 489,189 | Exempt: 2,246 | TRF Vol: 773,330 | Short Ratio: 63.3% | Off-exchange volume (dark pool + OTC)
May 4, 2026
earnings_calendar
VRTX Q1 2026 Earnings After Market Close — 2026-05-04
EPS est: $4.53 | Rev est: $3.1B
May 4, 2026
dark_pool
Dark Pool: VRTX — 1.7M shares, 64,650 trades
Week starting 2026-05-04. Total ATS volume: 1,683,411 shares across 64,650 trades.
May 4, 2026
short_volume
Short Volume: VRTX — 57.7% short (0.3M / 0.6M)
Short: 343,481 | Exempt: 12,088 | TRF Vol: 595,055 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
May 4, 2026
earnings_calendar
VRTX Q1 2026 Earnings Scheduled — 2026-05-04
Apr 27, 2026
dark_pool
Dark Pool: VRTX — 1.3M shares, 57,485 trades
Week starting 2026-04-27. Total ATS volume: 1,321,612 shares across 57,485 trades.
Apr 24, 2026
short_interest
FTD: VRTX — 1,290 shares ($0.6M) failed to deliver
Settlement: 20260424, Price: $435.10, FTD Value: $561,279, VERTEX PHARMACEUTICALS INC
Apr 20, 2026
dark_pool
Dark Pool: VRTX — 1.1M shares, 42,363 trades
Week starting 2026-04-20. Total ATS volume: 1,053,093 shares across 42,363 trades.
Apr 16, 2026
short_interest
FTD: VRTX — 2,143 shares ($0.9M) failed to deliver
Settlement: 20260416, Price: $441.70, FTD Value: $946,563.1, VERTEX PHARMACEUTICALS INC
Apr 15, 2026
short_volume
Short Volume: VRTX — 62.7% short (0.4M / 0.6M)
Short: 353,036 | Exempt: 422 | TRF Vol: 563,065 | Short Ratio: 62.7% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
Clinical Trial
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older
Phase Phase 3 — COMPLETED
Mar 17, 2026
FDA
ALYFTREK
Supplemental Approval — Labeling — VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR — TABLET — ORAL
Mar 17, 2026
FDA
ALYFTREK
Supplemental Approval — Labeling — VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR — TABLET — ORAL
Mar 3, 2026
Clinical Trial
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Feb 28, 2026
Clinical Trial
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Sep 25, 2025
FDA
SYMDEKO (COPACKAGED)
Supplemental Approval — Labeling — TEZACAFTOR AND IVACAFTOR — TABLET
Sep 25, 2025
FDA
ORKAMBI
Supplemental Approval — Labeling — LUMACAFTOR AND IVACAFTOR — GRANULE — ORAL
Sep 25, 2025
FDA
TRIKAFTA (COPACKAGED)
Supplemental Approval — Labeling — ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR — GRANULES